BOSTON, Jan 5 (Reuters) - An ovarian cancer drug under development by Genentech Inc. and Roche Holding AG failed to meet the main goal of a mid-stage trial, an analyst said, citing an interview with the company. Jason Kantor, an analyst at RBC Capital Markets Corp., said data from a Phase II trial of the experimental drug pertuzumab did not stave off the disease by a statistically significant amount.
